

Oral or Poster presentation code: g-63049

Valuation the effect of mesenchymal stem cell derived exosomes on male infertile as a novel treatment

Bahar Mehrabani1, Mohammad Khani-Eshratabadi2*


- Department of Medical Laboratory Sciences, Kashmar School of Nursing,
 Mashhad University of Medical sciences, Mashhad, Iran
- 2. Department of Hematology and Blood Transfusion Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran

Microvesicles




Introduction:


Infertility is now discussed to be a global health issue affecting about 15% of couples worldwide and It may arise from agents relevant to the male (30%), including varicocele, undescended testes, testicular cancer, and azoospermia. The novel experimental methods of the infertility treatment are stem cell and exosome applications. Because of the limitations using live cells injections and also the therapeutic effect of their paracrine substances, Mesenchymal Stem Cells derived exosomes











They can induce cell proliferation, cell viability, migration, oogenesis, spermatogenesis, capacitation and acrosome reaction. Studies results have shown the MSC-EXO ability to regenerate the damaged sperm, treating asthenozoospermia by their repairing molecules and counteracting with the reactive oxygen species. Also, it has been reported that MSC-EXO are able to induce the process of spermatogenesis in the testes of infertile animal models



Conclusion:

Male infertility is very complicated pathogenically and there is no ideal method for its treatment. These findings indicate that may be exosomes secreted by mesenchymal stem cells helpful in the novel treatments of male infertility.

Keywords:

Exosome, Mesenchymal Stem Cell, Male Infertility and Treatment.

Microvesicles



Reference

- Othman T, Herrera A, Mei M. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? Current Hematologic Malignancy Reports. 2021 Feb;16:1-7.
- Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. American journal of hematology. 2020 Aug;95(8):978-89.
- Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C. New treatment algorithms in Hodgkin lymphoma: too much or too little? American Society of Clinical Oncology Educational Book. 2018 May 1;38:626-36.
- LaCasce AS. Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease. Hematological oncology. 2019 Jun;37:87-91.
- Cabrera ME, Puga B, Torres V, Salinas M. Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile. Revista médica de Chile. 2019 Apr;147(4):437-43.